Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment : Evidence from Preclinical Studies

Thymocpinone (TO). the main bioactive component of Nigella saliva. has been found to exhibit anticancer effects In numerous preclinical studies. Due to its mutate/gating nature. TO interferes in a wide range of tumorigenic processes and counteracts carcinogenesis malignant growth, hvasion, migration, and anglogenesis. Moreover. TO can specifically sensitize tumor cells toward conventional cancer treatments (e.g.. radiotherapy, chemotherapy. and immunotherapy) and simultaneously minimize therapy-associated toxic effects in normal cells. In this review. we summarized the adruvani potential of TO as observed in various in vitro and in vivo animal models and discussed the pharmacological properties of TO to rationalize Its supplementary role In potentiating the efficacy of standard therapeutic modalities namely surgery. radiotherapy. chemotherapy. and immunotherapy Altogether, we suggest further comprehensive evaluation of TO in preclinical and clinical levels to delineate its implied utility as a novel complementary adjwant therapy for cancer treatment.